A team of researchers at VCU Massey Comprehensive Cancer Center has identified a new pathway through which mutations in the tumor suppressor p53 gene—found very frequently in human tumors—hijack DNA ...

Co-occurring alterations in EGFR-mutant NSCLC are increasingly detected via broad NGS and may signal aggressive biology, prompting interest in escalation strategies that address concurrent drivers.

Discover how lifestyle risks are impacting cancer cases in Singapore and the multi-faceted approach needed for effective ...

Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual immunotherapy. This episode, titled Dual Immunotherapy Strategies in Metastatic ...

A curious pattern in cancer statistics has puzzled scientists for decades. While cancer risk climbs steadily through middle age and beyond, it levels off and even declines among the oldest populations ...

Aging is associated with increased risk for nearly every lung disease, including acute conditions like pneumonia and chronic diseases like chronic obstructive pulmonary disease, idiopathic pulmonary ...

The approval was based on a cohort of treatment-naïve patients in the Beamion LUNG-1 trial who had unresectable or metastatic, non-squamous NSCLC with HER2 tyrosine kinase domain mutations.

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026Global pivotal Phase 3 ...

A leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.

By Tarun Sai Lomte Scientists reveal how evolution within our own tissues can drive disease, protect cells, and uncover hidden therapeutic targets for future precision medicine. Somatic genomics ...

Blood tests are the most common way for health professionals to detect and diagnose a range of medical conditions. But can it ...